Wang Jinyu, Xiong Ke, Zhao Shanliang, Zhang Chao, Zhang Jianwen, Xu Lei, Ma Aiguo
Institute of Nutrition and Health, School of Public Health, Qingdao University, Qingdao, China.
Linyi People's Hospital, Linyi, China.
Front Microbiol. 2020 Jan 30;11:53. doi: 10.3389/fmicb.2020.00053. eCollection 2020.
Gut microbiota dysbiosis has adverse health effects on human body. Multi-drug-resistant tuberculosis (MDR-TB) treatment uses a variety of antibiotics typically for more than 20 months, which may induce gut microbiota dysbiosis. The aim of this study is to investigate the long-term effects of MDR-TB treatment on human gut microbiota and its related health consequences. A total of 76 participants were recruited at a hospital in Linyi, China. The study included one active MDR-TB treatment group, one recovered group from MDR-TB and two treatment-naive tuberculosis groups as control. The two treatment-naïve tuberculosis groups were constructed to match the sex and the age of the active MDR-TB treatment and the recovered group, respectively. The fecal and blood samples were collected and analyzed for gut microbiota and metabolic parameters. An altered gut microbiota community and a loss of richness were observed during the MDR-TB treatment. Strikingly, 3-8 years after recovery and discontinuing the treatment, the gut microbiota still exhibited an altered taxonomic composition ( = 0.001) and a 16% decrease in richness ( = 0.018) compared to the gut microbiota before the treatment. The abundance of fifty-eight bacterial genera was significantly changed in the MDR-TB recovered group versus the untreated control group. Although there were persistent and pervasive gut microbiota alterations, no gastrointestinal symptom such as abdominal pain, diarrhea, nausea, flatulence, and constipation was observed in the recovered group. However, chronic disorders may be indicated by the elevated level of low-density lipoprotein cholesterol (LDLC) ( = 0.034) and total cholesterol (TC) ( = 0.017). These adverse lipid changes were associated with the altered gut bacterial taxa, including phylum Firmicutes and Verrucomicrobia and genera , , , , , , , , , and . Collectively, MDR-TB treatment induced a lasting gut microbiota dysbiosis, which was associated with unfavorable changes in lipid profile.
肠道微生物群失调对人体健康有不利影响。耐多药结核病（MDR-TB）治疗通常使用多种抗生素，疗程超过20个月，这可能会导致肠道微生物群失调。本研究的目的是调查耐多药结核病治疗对人体肠道微生物群的长期影响及其相关的健康后果。在中国临沂的一家医院共招募了76名参与者。该研究包括一个耐多药结核病治疗活跃组、一个耐多药结核病康复组和两个未接受过治疗的结核病组作为对照。构建两个未接受过治疗的结核病组分别与耐多药结核病治疗活跃组和康复组的性别和年龄相匹配。收集粪便和血液样本，分析肠道微生物群和代谢参数。在耐多药结核病治疗期间观察到肠道微生物群落改变和丰富度降低。令人惊讶的是，在康复并停止治疗3至8年后，与治疗前的肠道微生物群相比，肠道微生物群的分类组成仍然发生了改变（P = 0.001），丰富度降低了16%（P = 0.018）。与未治疗的对照组相比，耐多药结核病康复组中有58个细菌属的丰度发生了显著变化。尽管存在持续且普遍的肠道微生物群改变，但康复组中未观察到腹痛、腹泻、恶心、肠胃胀气和便秘等胃肠道症状。然而，低密度脂蛋白胆固醇（LDLC）水平升高（P = 0.034）和总胆固醇（TC）水平升高（P = 0.017）可能表明存在慢性疾病。这些不利的脂质变化与肠道细菌分类群的改变有关，包括厚壁菌门、疣微菌门以及属、、、、、、、、和。总体而言，耐多药结核病治疗导致了持久的肠道微生物群失调，这与脂质谱的不利变化有关。
